Fresenius Medical Care AG (NYSE:FMS) Sees Large Decline in Short Interest

Fresenius Medical Care AG (NYSE:FMS) saw a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 683,300 shares, a decline of 8.6% from the September 15th total of 747,500 shares. Based on an average daily volume of 304,500 shares, the short-interest ratio is presently 2.2 days.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Truist Financial upped their target price on Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a report on Monday, October 7th. StockNews.com began coverage on Fresenius Medical Care in a report on Tuesday, October 8th. They issued a “strong-buy” rating for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $23.00.

Hedge Funds Weigh In On Fresenius Medical Care

Several hedge funds have recently made changes to their positions in the stock. Wulff Hansen & CO. raised its position in Fresenius Medical Care by 1,809.0% during the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after purchasing an additional 325,439 shares in the last quarter. Triasima Portfolio Management inc. grew its stake in shares of Fresenius Medical Care by 27.4% in the second quarter. Triasima Portfolio Management inc. now owns 85,430 shares of the company’s stock worth $1,631,000 after acquiring an additional 18,360 shares during the period. QRG Capital Management Inc. boosted its stake in shares of Fresenius Medical Care by 10.9% in the 2nd quarter. QRG Capital Management Inc. now owns 60,309 shares of the company’s stock worth $1,151,000 after buying an additional 5,946 shares during the last quarter. Veracity Capital LLC increased its position in shares of Fresenius Medical Care by 172.2% during the 1st quarter. Veracity Capital LLC now owns 53,023 shares of the company’s stock valued at $1,022,000 after purchasing an additional 33,543 shares during the last quarter. Finally, Creative Planning grew its position in Fresenius Medical Care by 18.9% during the second quarter. Creative Planning now owns 40,140 shares of the company’s stock valued at $766,000 after buying an additional 6,373 shares during the period. 8.25% of the stock is currently owned by hedge funds and other institutional investors.

Fresenius Medical Care Stock Up 0.0 %

NYSE FMS traded up $0.01 on Thursday, reaching $20.04. The company had a trading volume of 173,597 shares, compared to its average volume of 372,193. The company has a quick ratio of 1.09, a current ratio of 1.46 and a debt-to-equity ratio of 0.45. The company’s fifty day moving average is $19.92 and its 200 day moving average is $20.05. Fresenius Medical Care has a 52-week low of $16.37 and a 52-week high of $22.76. The stock has a market capitalization of $11.76 billion, a P/E ratio of 22.52, a P/E/G ratio of 1.06 and a beta of 0.91.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.38. The company had revenue of $5.13 billion for the quarter, compared to the consensus estimate of $5.28 billion. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. Sell-side analysts anticipate that Fresenius Medical Care will post 1.52 earnings per share for the current fiscal year.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.